Physician profile
Michael Koop
NPI 1033169842
$2,259.15
in general payments reported to CMS, 2019-2025
15 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $193 · 2021: $184 · 2022: $359 · 2023: $314 · 2024: $381 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.71 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $268.77 | 2019-2025 | Cequa |
| Alcon Vision LLC | $209.51 | 2020-2024 | Acrysof Iq Panoptix Uv Iol, Rocklatan |
| Novartis Pharmaceuticals Corporation | $201.30 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $178.13 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.38 | 2019-2021 | |
| Harrow Eye, LLC | $95.64 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $78.33 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $66.04 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $62.74 | 2022-2023 | Vyzulta, Miebo |
| Thea Pharma INC. | $49.39 | 2024-2025 | Iyuzeh |
| Allergan, INC. | $49.21 | 2019-2022 | |
| Sight Sciences, INC. | $26.90 | 2022 | |
| Biotissue Holdings INC. | $24.70 | 2024 | |
| Shire North American Group INC | $22.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Koop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.